Acquiring evidence for precision prostate cancer care

por Mateo, J., Carreira, S., de Bono, J. S.
Publicado 2017

Targeting IGF-1R: throwing out the baby with the bathwater?

por Basu, B, Olmos, D, de Bono, J S
Publicado 2011

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

por Ang, J E, Olmos, D, de Bono, J S
Publicado 2009

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

por Stewart, A., Thavasu, P., de Bono, J. S., Banerji, U.
Publicado 2015

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

por Lheureux, S., Denoyelle, C., Ohashi, P. S., De Bono, J. S., Mottaghy, F. M.
Publicado 2017

What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an e...

por Stapleton, Sarah, Darlington, Anne-Sophie Emma, de Bono, J S, Wiseman, Theresa
Publicado 2022

Clinical anticancer drug development: targeting the cyclin-dependent kinases

por Benson, C, Kaye, S, Workman, P, Garrett, M, Walton, M, de Bono, J
Publicado 2005

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

por Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S
Publicado 2008

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

por Attard, G, Sarker, D, Reid, A, Molife, R, Parker, C, de Bono, J S
Publicado 2006

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience

por Olmos, D, Arkenau, H-T, Ang, J E, de Bono, J S, Judson, I, Kaye, S B
Publicado 2008

The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

por Kumar, R, Geuna, E, Michalarea, V, Guardascione, M, Naumann, U, Lorente, D, Kaye, S B, de Bono, J S
Publicado 2015

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

por Wilbaux, M, Tod, M, De Bono, J, Lorente, D, Mateo, J, Freyer, G, You, B, Hénin, E
Publicado 2015

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado 2009

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

por Brunetto, A T, Sarker, D, Papadatos-Pastos, D, Fehrmann, R, Kaye, S B, Johnston, S, Allen, M, De Bono, J S, Swanton, C
Publicado 2010

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

por Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O.
Publicado 2013

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer

por Thiery-Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Thangavelu, K., Ozatilgan, A., Poole, E.M., Eisenberger, M., de Bono, J.
Publicado 2021

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

por Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S
Publicado 2014

A decade of clinical development of PARP inhibitors in perspective

por Mateo, J, Lord, C J, Serra, V, Tutt, A, Balmaña, J, Castroviejo-Bermejo, M, Cruz, C, Oaknin, A, Kaye, S B, de Bono, J S
Publicado 2019

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

por Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Publicado 2007

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

por Goodman, O B, Flaig, T W, Molina, A, Mulders, P F A, Fizazi, K, Suttmann, H, Li, J, Kheoh, T, de Bono, J S, Scher, H I
Publicado 2014